VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
NCT04654052
Acute Coronary Syndrome, Acute Myocardial Infarction
El Palmar, Murcia, Spain
View Trial DetailsNCT Number: NCT04611607
This registry will provide information about the efficacy and safety of cangrelor in a very high-risk group of patients with acute myocardial infarction undergoing PCI. It will not only include patients with cardiogenic shock, but a variety of patients not able to swallow tablets, such as those after CPR and/or with invasive or non-invasive ventilation. Therefore it will provide information about the use of cangrelor beyond the current knowledge.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Universitätsklinikum Graz, Graz, Austria
This registry is a non-interventional, multicentre, retrospective cohort study in patients with acute myocardial infarction undergoing PCI after CRP, ventilated and/or with cardiogenic shock.
The study is purely observational; data will be documented retrospectively based on available medical records. No additional data will be collected, no study-related treatment will be initiated.
About 10 - 20 high-volume PCI clinics in Germany treating patients with myocardial infarction are eligible for participation. Participating sites will be given a maximum of 6 months for retrospectively documenting eligible patients.
Eligible are all patients with acute myocardial infarction (STEMI, NSTEMI) who underwent PCI after CRP, ventilated and/or with cardiogenic shock and were treated with cangrelor during index procedure. It is planned to enrol about 400 patients in total. Patient characteristics, procedural details and clinical events occurring during the period between index MI and discharge or death (whichever came first) will be documented based on the relevant existing medical charts of the patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No explicit medical exclusion criteria are stated to avoid selection bias.
Time frame: from procedure for index MI up to 48 hours
Rate of stent thromboses
Time frame: from procedure for index MI up to 48 hours
Rate of recurrent myocardial infarction according to the universal definition of MI
Time frame: from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days
Rate of stent thromboses
Time frame: from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days
Rate of recurrent myocardial infarction according to the universal definition of MI
Time frame: from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days
Rate of bleeding complication according to BARC definition
Time frame: from procedure for index MI until discharge from hospital; up to 30 days
Rate of death
Looking for future studies?
Notify MeIHF GmbH - Institut für Herzinfarktforschung
Other
Acronym: CAN-SHOCK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04654052
Acute Coronary Syndrome, Acute Myocardial Infarction
El Palmar, Murcia, Spain
View Trial DetailsNCT04064593
Acute Myocardial Infarction, Apnea
Paris, France
View Trial DetailsNCT05853042
Acute Coronary Syndrome, Acute Myocardial Infarction
Minneapolis, Minnesota, United States
View Trial DetailsNCT06457815
Acute Myocardial Infarction
Middlesbrough, Teesside, United Kingdom
View Trial Details